Celldex Therapeutics, Inc. (CLDX) Stock price, Description, News & Info

#Thinksabio latest news

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study